Article
Deletion of the RNA‐editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice
18 Sept 2012
Abstract excerpt
Patients with chronic myelogenous leukemia (CML) respond well to tyrosine kinase inhibitors (TKIs) of the Bcr-Abl oncoprotein. However, intolerance and resistance to these agents remains a challenge, and TKIs are unable to eradicate rare leukemia-initiating cells. Leukemia treatment would benefit from a better understanding of molecular signals that are necessary for the survival of leukemia-initiating cells but...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
